The Swiss voice in the world since 1935

Roche taps AI to find cancer patients after trial success

roche tower in basel
Roche HQ in the northwestern Swiss city of Basel. © Keystone / Gaetan Bally

Roche Holding AG’s lung cancer drug scored a big win against a standard therapy in a study this week. Now, the Swiss drugmaker is turning to artificial intelligence to find patients who can benefit. 

When given after surgery to remove lung tumours, Roche’s Alecensa cut the risk of either cancer recurrence or death by 76% compared with standard chemotherapy, according to results from a primary analysis of the trial released Wednesday. The drug could “potentially alter the course of this disease,” Roche Chief Medical Officer Levi Garraway said in a statement. 

But finding patients to treat may be difficult: the study examined the effects on people with an error in a gene called ALK that’s found in only about 4% to 5% of lung cancer patients. Most of them are younger and less likely to have smoked than typical lung tumour patients, and often go undiagnosed early on. 

+ Dive into the history of Swiss pharma firms in our long-form featureExternal link

To solve the problem, Roche will use an AI collaboration with Israeli tech company Medial EarlySign Ltd. to help doctors determine when to use CT scans. While the technology, called LungFlag, doesn’t currently detect ALK-positive patients, the company said on Saturday that it’s actively exploring how to expand it so they can benefit. 

That will help find tumours before they spread and while needed surgery is still possible, said Charlie Fuchs, Roche’s head of oncology and haematology drug development. 

“Sometimes when you really use deep data algorithms, you may find things that identify people who are non-smokers and yet at risk,” Fuchs said in an interview. “We hope more patients can be found early and benefit from this.”

Roche has said it will file the Alecensa study results with regulators for approval. The full results were presented Saturday at the European Society for Medical Oncology meeting in Madrid. Alecensa is already approved in the US, Europe, Japan and China for patients with ALK-positive metastatic lung cancer. 

Analysts anticipate that Alecensa will generate CHF1.56 billion ($1.75 billion) in sales this year. That it would be a blockbuster medicine even though it treats such a small portion of lung cancer patients shows that effective drugs don’t have to serve a big patient population to be scientific and financial successes, Fuchs said. 

Popular Stories

News

One person consumes 4.8 megawatt hours of electricity

More

One person consumes 4.8 megawatt hours of electricity

This content was published on On average, the Swiss consume 4.8 megawatt hours of electricity per year. According to Velobiz.de, this is roughly equivalent to the amount generated by all 176 cyclists in the Tour de France during the entire race.

Read more: One person consumes 4.8 megawatt hours of electricity
Lisa Mazzone criticises the Federal Council's neo-liberal policy

More

Foreign Affairs

Green party leader criticises government’s neo-liberal policy

This content was published on The Green Party delegates' meeting opened on Saturday morning in Vicques (JU) with a speech by party president Lisa Mazzone. Mazzone took particular aim at the Federal Council's policy towards the United States.

Read more: Green party leader criticises government’s neo-liberal policy
Safra Sarasin and a former asset manager sentenced

More

Swiss Politics

Safra Sarasin private bank and former asset manager sentenced

This content was published on The Office of the Attorney General of Switzerland has fined private bank J. Safra Sarasin CHF3.5 million for aggravated money laundering. A former bank employee received a six-month suspended prison sentence.

Read more: Safra Sarasin private bank and former asset manager sentenced
1MDB affair: JPMorgan to pay CHF 270 million

More

Swiss Politics

JPMorgan to pay CHF270 million to settle 1MDB claims

This content was published on JPMorgan Chase has agreed to pay CHF270 million to the Malaysian government to settle all issues related to its role in the 1MDB financial scandal.

Read more: JPMorgan to pay CHF270 million to settle 1MDB claims
Philippe Lazzarini has overseen UNRWA since 2020.

More

Foreign Affairs

UNRWA boss Lazzarini to step down in March 2026

This content was published on Philippe Lazzarini will step down as head of the United Nations Relief and Works Agency for Palestinian Refugees (UNRWA) at the end of his term in March, he announced on Thursday.

Read more: UNRWA boss Lazzarini to step down in March 2026

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR